Teva has launched a digitally-enabled inhaler ... The GoResp Digihaler – which delivers inhaled corticosteroid budesonide and long-acting beta agonist formoterol – has built-in sensors that ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year appears to have investors spooked. Teva on Wednesday reported that ...

Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus TEVA. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Data from a new randomized, placebo-controlled trial have demonstrated the efficacy of budesonide in inducing remission of this disease; this study is an important contribution to this field.

A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers. Developed by Australian medtech firm ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Teva reported growth for the second year in a row. Despite exceeding Wall Street targets, the company's guidance came up short. Teva reported earnings before trading began on Wednesday. The ...